OPN1MW and COVID-19: The trial involved 109 subjects with mild to moderate symptoms of COVID-19 related [62], subdivided into 49 subjects in the CBD group, who were administered oral CBD at a dosage of 300 mg daily, and 42 subjects in the placebo group.